These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 37962393)

  • 21. An FP-CIT PET comparison of the differences in dopaminergic neuronal loss between idiopathic Parkinson disease with dementia and without dementia.
    Song IU; Kim YD; Cho HJ; Chung SW; Chung YA
    Alzheimer Dis Assoc Disord; 2013; 27(1):51-5. PubMed ID: 22354157
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Additional Role of Midbrain F-18 FP-CIT Uptake on PET in Evaluation of Essential Tremor and Parkinsonism.
    Lee H; Sung YH; Hwang KH
    Curr Med Imaging; 2023; 19(9):1041-1051. PubMed ID: 36734891
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Brain perfusion scintigraphy with 99mTc-HMPAO or 99mTc-ECD and 123I-beta-CIT single-photon emission tomography in dementia of the Alzheimer-type and diffuse Lewy body disease.
    Donnemiller E; Heilmann J; Wenning GK; Berger W; Decristoforo C; Moncayo R; Poewe W; Ransmayr G
    Eur J Nucl Med; 1997 Mar; 24(3):320-5. PubMed ID: 9143472
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association between heart rate variability and striatal dopamine depletion in Parkinson's disease.
    Kitagawa T; Umehara T; Oka H; Shiraishi T; Sato T; Takatsu H; Nakahara A; Matsuno H; Bono K; Omoto S; Murakami H; Sengoku R; Iguchi Y
    J Neural Transm (Vienna); 2021 Dec; 128(12):1835-1840. PubMed ID: 34559319
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Striatal dopamine transporter in dementia with Lewy bodies and Parkinson disease: a comparison.
    Walker Z; Costa DC; Walker RW; Lee L; Livingston G; Jaros E; Perry R; McKeith I; Katona CL
    Neurology; 2004 May; 62(9):1568-72. PubMed ID: 15136683
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Decreased striatal dopamine transporter uptake in the non-fluent/agrammatic variant of primary progressive aphasia.
    Gil-Navarro S; Lomeña F; Cot A; Lladó A; Montagut N; Castellví M; Bosch B; Rami L; Antonell A; Balasa M; Pavia J; Iranzo A; Molinuevo JL; Sánchez-Valle R
    Eur J Neurol; 2013 Nov; 20(11):1459-e126. PubMed ID: 23679075
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET.
    Hansen AK; Knudsen K; Lillethorup TP; Landau AM; Parbo P; Fedorova T; Audrain H; Bender D; Østergaard K; Brooks DJ; Borghammer P
    Brain; 2016 Jul; 139(Pt 7):2039-49. PubMed ID: 27190023
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of FP-CIT SPECT with F-DOPA PET in patients with de novo and advanced Parkinson's disease.
    Eshuis SA; Maguire RP; Leenders KL; Jonkman S; Jager PL
    Eur J Nucl Med Mol Imaging; 2006 Feb; 33(2):200-9. PubMed ID: 16228235
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Salivary Gland Uptake on
    Kang SY; Yun JY; Kang YK; Moon BS; Yoon HJ; Yoo MY; Kim BS
    Korean J Radiol; 2023 Jul; 24(7):690-697. PubMed ID: 37404111
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chronic motor cortex stimulation in patients with advanced Parkinson's disease and effects on striatal dopaminergic transmission as assessed by 123I-FP-CIT SPECT: a preliminary report.
    Di Giuda D; Calcagni ML; Totaro M; Cocciolillo F; Piano C; Soleti F; Fasano A; Cioni B; Bentivoglio AR; Giordano A
    Nucl Med Commun; 2012 Sep; 33(9):933-40. PubMed ID: 22735298
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dopaminergic Depletion, β-Amyloid Burden, and Cognition in Lewy Body Disease.
    Yoo HS; Lee S; Chung SJ; Lee YH; Lee PH; Sohn YH; Lee S; Yun M; Ye BS
    Ann Neurol; 2020 May; 87(5):739-750. PubMed ID: 32078179
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serotonergic deficits in dementia with Lewy bodies with concomitant Alzheimer's disease pathology: An
    van der Zande JJ; Joling M; Happach IG; Vriend C; Scheltens P; Booij J; Lemstra AW
    Neuroimage Clin; 2020; 25():102062. PubMed ID: 31790878
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The utility of the combination of a SPECT study with [123I]-FP-CIT of dopamine transporters and [123I]-MIBG myocardial scintigraphy in differentiating Parkinson disease from other degenerative parkinsonian syndromes.
    Uyama N; Otsuka H; Shinya T; Otomi Y; Harada M; Sako W; Izumi Y; Kaji R; Watanabe Y; Takashi S; Kunikane Y
    Nucl Med Commun; 2017 Jun; 38(6):487-492. PubMed ID: 28410288
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Striatal Dopamine Transporter Modulation After Rotigotine: Results From a Pilot Single-Photon Emission Computed Tomography Study in a Group of Early Stage Parkinson Disease Patients.
    Rossi C; Genovesi D; Marzullo P; Giorgetti A; Filidei E; Corsini GU; Bonuccelli U; Ceravolo R
    Clin Neuropharmacol; 2017; 40(1):34-36. PubMed ID: 27941527
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Striatal dopamine transporter imaging correlates with depressive symptoms and tower of London task performance in Parkinson's disease.
    Rektorova I; Srovnalova H; Kubikova R; Prasek J
    Mov Disord; 2008 Aug; 23(11):1580-7. PubMed ID: 18618663
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical and Dopamine Transporter Imaging Trajectories in a Cohort of Parkinson's Disease Patients with GBA Mutations.
    Caminiti SP; Carli G; Avenali M; Blandini F; Perani D
    Mov Disord; 2022 Jan; 37(1):106-118. PubMed ID: 34596920
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Striatal dopamine activity and myocardial
    Oh YS; Kim JS; Yoo SW; Hwang EJ; Lyoo CH; Lee KS
    Parkinsonism Relat Disord; 2019 Jun; 63():156-161. PubMed ID: 30796009
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Weight loss is associated with rapid striatal dopaminergic degeneration in Parkinson's disease.
    Pak K; Shin HK; Kim EJ; Lee JH; Lyoo CH; Son J; Lee MJ
    Parkinsonism Relat Disord; 2018 Jun; 51():67-72. PubMed ID: 29510907
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Age and gender effects on striatal dopamine transporter density and cerebral perfusion in individuals with non-degenerative parkinsonism: a dual-phase
    Kim JY; Kang SY; Moon BS; Kim BS; Jeong JH; Yoon HJ
    EJNMMI Res; 2024 Jul; 14(1):65. PubMed ID: 39017925
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nigrostriatal dopamine transporter availability, and its metabolic and clinical correlates in Parkinson's disease patients with impulse control disorders.
    Navalpotro-Gomez I; Dacosta-Aguayo R; Molinet-Dronda F; Martin-Bastida A; Botas-Peñin A; Jimenez-Urbieta H; Delgado-Alvarado M; Gago B; Quiroga-Varela A; Rodriguez-Oroz MC
    Eur J Nucl Med Mol Imaging; 2019 Sep; 46(10):2065-2076. PubMed ID: 31273436
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.